Moderna..

 

There was one piece of data in Moderna's late-stage results that just might give it an advantage over BNT162b2. The biotech said that there were 30 severe cases of COVID-19 observed in its clinical study. All of those cases occurred in the group of participants receiving placebo with none in the group receiving mRNA-1273.

Pfizer and BioNTech announced that 10 severe cases of COVID-19 were observed in its late-stage study. Nine of those occurred in the placebo group with one in the group vaccinated with BNT162b2.

Pfizer and BioNTech designed special thermal shippers filled with dry ice that maintain the needed temperature. These shippers can be used as temporary storage units for up to 15 days by refilling with more dry ice as needed.

Moderna's mRNA-1273 is a messenger RNA (mRNA) vaccine like BNT162b2. It also initially required ultracold storage. However, Moderna modified its approach to address this issue. 

Its coronavirus vaccine can now remain stable at temperatures between 36 degrees and 46 degrees Fahrenheit for 30 days. This means that standard refrigerators can be used to store mRNA-1273. The vaccine also will remain stable at minus four degrees Fahrenheit for up to six months and at room temperature for up to 12 hours.